Cover Image
市場調查報告書

美國的藥物輸送設備市場未來展望:中央靜脈導管、輸液系統、無針頭注射器、定量噴霧吸入器 (MDI)

United States Drug Delivery Devices Market Outlook to 2023 - Central Venous Catheters, Infusion Systems, Needle Free Injections and Metered Dose Inhaler Devices

出版商 GlobalData 商品編碼 537203
出版日期 內容資訊 英文 980 Pages
訂單完成後即時交付
價格
Back to Top
美國的藥物輸送設備市場未來展望:中央靜脈導管、輸液系統、無針頭注射器、定量噴霧吸入器 (MDI) United States Drug Delivery Devices Market Outlook to 2023 - Central Venous Catheters, Infusion Systems, Needle Free Injections and Metered Dose Inhaler Devices
出版日期: 2017年08月01日 內容資訊: 英文 980 Pages
簡介

本報告提供美國的各種藥物輸送設備 (藥物輸送設備)的市場相關分析,整體市場趨勢的變化和預測 (過去、今後8年份),各產品類型詳細趨勢,主要企業、流通管道的市場佔有率,主要的開發中產品的目前臨床實驗情形,近來的資本交易、企業發展的動向,主要企業簡介等調查評估。

第1章 目錄

第2章 簡介

  • 本報告概要
  • 藥物輸送設備市場明細
  • 本報告的分析對象市場定義

第3章 美國的藥物輸送設備市場

  • 市場收益額趨勢:以金額為準 (總計15年份)
  • 市場收益額結構:以金額為準
  • 市場收益額:各類別佔有率
  • 市場收益額:各類別佔有率比較 (總計15年份)
  • 市場收益額的成果值:以金額為準 (過去8年份)
  • 市場收益額的預測值:以金額為準 (今後8年份)
  • 市場規模趨勢:以數量為準 (總計15年份)
  • 市場規模的成果值:以數量為準 (過去8年份)
  • 市場規模的預測值:以數量為準 (今後8年份)
  • 市場收益額佔有率:各企業

第4章 美國的中央靜脈導管市場

  • 市場收益額結構:以金額為準
  • 市場收益額:各類別佔有率
  • 市場收益額的成果值:以金額為準 (過去8年份)
  • 市場收益額的預測值:以金額為準 (今後8年份)
  • 市場規模的成果值:以數量為準 (過去8年份)
  • 市場規模的預測值:以數量為準 (今後8年份)
  • 市場收益額佔有率:各流通管道
  • 市場收益額佔有率:各企業

第5章 美國的輸液系統市場

第6章 美國的無針頭注射器市場

第7章 美國的定量噴霧吸入器 (MDI) 市場

第8章 主要企業簡介:美國的藥物輸送設備市場

  • GlaxoSmithKline Plc
  • Teleflex Inc
  • AstraZeneca Plc
  • C. R. Bard Inc
  • Hospira Inc
  • Becton Dickinson and Co
  • Edwards Lifesciences Corp
  • Baxter International Inc
  • Boehringer Ingelheim GmbH
  • Medtronic Plc
  • Smiths Medical
  • B. Braun Melsungen AG
  • Pfizer Inc
  • Fresenius Kabi AG
  • Merck & Co Inc

第9章 藥物輸送設備市場的開發中產品

第10章 資本交易環境

  • 企業收購
  • 資產交易
  • 發行公司債券
  • 股票上市
  • 企業合併
  • 產業聯盟
  • 私人股權 (非上市股票交易)
  • 風險企業融資

第11章 近幾年主要的動向

  • 來自企業的發表 (企業傳訊)
  • 公佈財報
  • 政府、公益相關
  • 法規、規定相關
  • 其他主要動向
  • 產品新聞
  • 策略、產業計畫

第12章 附錄

圖表一覽

目錄
Product Code: GDMEMC0241DB

GlobalData's new report, "United States Drug Delivery Devices Market Outlook to 2023", provides key market data on the United States Drug Delivery Devices market. The report provides value, in millions of US dollars and volume (in units) within market categories - Central Venous Catheters, Needle Free Injections, Infusion Systems and Metered Dose Inhaler Devices.

The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope:

  • Market size and company share data for Drug Delivery Devices market categories - Central Venous Catheters, Needle Free Injections, Infusion Systems and Metered Dose Inhaler Devices.
  • Annualized market revenues (USD million) and volume (units) data for each of the market categories. Data is provided from 2009 to 2016 and forecast to 2023.
  • 2016 company shares and distribution shares data for each of the market categories.
  • Global corporate-level profiles of key companies operating within the United States Drug Delivery Devices market.
  • Key players covered include GlaxoSmithKline Plc, AstraZeneca Plc, Hospira Inc, Becton Dickinson and Co, Boehringer Ingelheim GmbH, Baxter International Inc, Medtronic plc and others.

Reasons to buy:

  • Develop business strategies by identifying the key market categories poised for strong growth in the future.
  • Develop market-entry and market expansion strategies.
  • Design competition strategies by identifying who-stands-where in the market.
  • Develop investment strategies by identifying the key market categories expected to register strong growth in the near future.
  • What are the key distribution channels and what's the most preferred mode of product distribution - Identify, understand and capitalize.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. What Is This Report About?
  • 2.2. Drug Delivery Devices Market Segmentation
  • 2.3. Definitions of Markets Covered in the Report

3. Drug Delivery Devices Market, United States

  • 3.1. Drug Delivery Devices Market, United States, Revenue ($m), 2009-2023
  • 3.2. Drug Delivery Devices Market, United States, Revenue Mix ($m), 2016
  • 3.3. Drug Delivery Devices Market, United States, Category Contribution by Revenue ($m), 2016
  • 3.4. Drug Delivery Devices Market, United States, Category Comparison by Revenue ($m), 2009-2023
  • 3.5. Drug Delivery Devices Market, United States, Revenue ($m), 2009-2016
  • 3.6. Drug Delivery Devices Market, United States, Revenue ($m), 2016-2023
  • 3.7. Drug Delivery Devices Market, United States, Volume (Units), 2009-2023
  • 3.8. Drug Delivery Devices Market, United States, Volume (Units), 2009-2016
  • 3.9. Drug Delivery Devices Market, United States, Volume (Units), 2016-2023
  • 3.10. Drug Delivery Devices Market, United States, Company Share by Revenue ($m), 2016

4. Central Venous Catheters Market, United States

  • 4.1. Central Venous Catheters Market, United States, Revenue Mix ($m), 2016
  • 4.2. Central Venous Catheters Market, United States, Segment Contribution (%), 2016
  • 4.3. Central Venous Catheters Market, United States, Revenue ($m), 2009-2016
  • 4.4. Central Venous Catheters Market, United States, Revenue ($m), 2016-2023
  • 4.5. Central Venous Catheters Market, United States, Volume (Units), 2009-2016
  • 4.6. Central Venous Catheters Market, United States, Volume (Units), 2016-2023
  • 4.7. Central Venous Catheters Market, United States, Distribution Share by Revenue ($m), 2015-2016
  • 4.8. Central Venous Catheters Market, United States, Company Share by Revenue ($m), 2016

5. Infusion Systems Market, United States

  • 5.1. Infusion Systems Market, United States, Revenue Mix ($m), 2016
  • 5.2. Infusion Systems Market, United States, Segment Contribution (%), 2016
  • 5.3. Infusion Systems Market, United States, Revenue ($m), 2009-2016
  • 5.4. Infusion Systems Market, United States, Revenue ($m), 2016-2023
  • 5.5. Infusion Systems Market, United States, Volume (Units), 2009-2016
  • 5.6. Infusion Systems Market, United States, Volume (Units), 2016-2023
  • 5.7. Infusion Systems Market, United States, Distribution Share by Revenue ($m), 2015-2016
  • 5.8. Infusion Systems Market, United States, Company Share by Revenue ($m), 2016

6. Needle Free Injections Market, United States

  • 6.1. Needle Free Injections Market, United States, Revenue ($m), 2009-2016
  • 6.2. Needle Free Injections Market, United States, Revenue ($m), 2016-2023
  • 6.3. Needle Free Injections Market, United States, Volume (Units), 2009-2016
  • 6.4. Needle Free Injections Market, United States, Volume (Units), 2016-2023
  • 6.5. Needle Free Injections Market, United States, Distribution Share by Revenue ($m), 2015-2016
  • 6.6. Needle Free Injections Market, United States, Company Share by Revenue ($m), 2016

7. Metered Dose Inhaler Devices Market, United States

  • 7.1. Metered Dose Inhaler Devices Market, United States, Revenue ($m), 2009-2016
  • 7.2. Metered Dose Inhaler Devices Market, United States, Revenue ($m), 2016-2023
  • 7.3. Metered Dose Inhaler Devices Market, United States, Volume (Units), 2009-2016
  • 7.4. Metered Dose Inhaler Devices Market, United States, Volume (Units), 2016-2023
  • 7.5. Metered Dose Inhaler Devices Market, United States, Distribution Share by Revenue ($m), 2015-2016
  • 7.6. Metered Dose Inhaler Devices Market, United States, Company Share by Revenue ($m), 2016

8. Overview of Key Companies in United States, Drug Delivery Devices Market

  • 8.1. GlaxoSmithKline Plc
  • 8.2. Teleflex Inc
  • 8.3. AstraZeneca Plc
  • 8.4. C. R. Bard Inc
  • 8.5. Hospira Inc
  • 8.6. Becton Dickinson and Co
  • 8.7. Edwards Lifesciences Corp
  • 8.8. Baxter International Inc
  • 8.9. Boehringer Ingelheim GmbH
  • 8.10. Medtronic Plc
  • 8.11. Smiths Medical
  • 8.12. B. Braun Melsungen AG
  • 8.13. Pfizer Inc
  • 8.14. Fresenius Kabi AG
  • 8.15. Merck & Co Inc

9. Drug Delivery Devices Market Pipeline Products

10. Financial Deals Landscape

  • 10.1. Acquisition
  • 10.2. Asset Transactions
  • 10.3. Debt Offerings
  • 10.4. Equity Offerings
  • 10.5. Merger
  • 10.6. Partnerships
  • 10.7. Private Equity
  • 10.8. Venture Financing

11. Recent Developments

  • 11.1. Corporate Communications
  • 11.2. Financial Announcements
  • 11.3. Government and Public Interest
  • 11.4. Legal And Regulatory
  • 11.5. Other Significant Developments
  • 11.6. Product News
  • 11.7. Strategy And Business Planning

12. Appendix

  • 12.1. Research Methodology
  • 12.2. GlobalData Consulting
  • 12.3. Contact Us
  • 12.4. Disclaimer

List of Tables

  • Table 1: Drug Delivery Devices Market, United States, Revenue ($m), USD Constant, 2009-2023
  • Table 2: Drug Delivery Devices Market, United States, Category Contribution by Revenue ($m), 2016
  • Table 3: Drug Delivery Devices Market, United States, Category Comparison by Revenue ($m), 2009-2023
  • Table 4: Drug Delivery Devices Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016
  • Table 5: Drug Delivery Devices Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023
  • Table 6: Drug Delivery Devices Market, United States, Volume (Units), 2009-2023
  • Table 7: Drug Delivery Devices Market, United States, Volume (Units), Historic, 2009-2016
  • Table 8: Drug Delivery Devices Market, United States, Volume (Units), Forecast, 2016-2023
  • Table 9: Drug Delivery Devices Market, United States, Company Share by Revenue ($m), USD Constant, 2016
  • Table 10: Central Venous Catheters Market, United States, Segment Contribution (%), 2016
  • Table 11: Central Venous Catheters Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016
  • Table 12: Central Venous Catheters Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023
  • Table 13: Central Venous Catheters Market, United States, Volume (Units), Historic, 2009-2016
  • Table 14: Central Venous Catheters Market, United States, Volume (Units), Forecast, 2016-2023
  • Table 15: Central Venous Catheters Market, United States, Distribution Share by Revenue ($m), USD Constant, 2015-2016
  • Table 16: Central Venous Catheters Market, United States, Company Share by Revenue ($m), USD Constant, 2016
  • Table 17: Infusion Systems Market, United States, Segment Contribution (%), 2016
  • Table 18: Infusion Systems Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016
  • Table 19: Infusion Systems Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023
  • Table 20: Ambulatory Infusion Pumps Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016
  • Table 21: Syringe Pumps Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016
  • Table 22: Ambulatory Infusion Pumps Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023
  • Table 23: Syringe Pumps Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023
  • Table 24: Infusion Systems Market, United States, Volume (Units), Historic, 2009-2016
  • Table 25: Infusion Systems Market, United States, Volume (Units), Forecast, 2016-2023
  • Table 26: Ambulatory Infusion Pumps Market, United States, Volume (Units), Historic, 2009-2016
  • Table 27: Syringe Pumps Market, United States, Volume (Units), Historic, 2009-2016
  • Table 28: Ambulatory Infusion Pumps Market, United States, Volume (Units), Forecast, 2016-2023
  • Table 29: Syringe Pumps Market, United States, Volume (Units), Forecast, 2016-2023
  • Table 30: Infusion Systems Market, United States, Distribution Share by Revenue ($m), USD Constant, 2015-2016
  • Table 31: Infusion Systems Market, United States, Company Share by Revenue ($m), USD Constant, 2016
  • Table 32: Needle Free Injections Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016
  • Table 33: Needle Free Injections Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023
  • Table 34: Needle Free Injections Market, United States, Volume (Units), Historic, 2009-2016
  • Table 35: Needle Free Injections Market, United States, Volume (Units), Forecast, 2016-2023
  • Table 36: Needle Free Injections Market, United States, Distribution Share by Revenue ($m), USD Constant, 2015-2016
  • Table 37: Needle Free Injections Market, United States, Company Share by Revenue ($m), USD Constant, 2016
  • Table 38: Metered Dose Inhaler Devices Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016
  • Table 39: Metered Dose Inhaler Devices Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023
  • Table 40: Metered Dose Inhaler Devices Market, United States, Volume (Units), Historic, 2009-2016
  • Table 41: Metered Dose Inhaler Devices Market, United States, Volume (Units), Forecast, 2016-2023
  • Table 42: Metered Dose Inhaler Devices Market, United States, Distribution Share by Revenue ($m), USD Constant, 2015-2016
  • Table 43: Metered Dose Inhaler Devices Market, United States, Company Share by Revenue ($m), USD Constant, 2016
  • Table 44: Drug Delivery Devices Market Pipeline Products
  • Table 45: Peaceful Union Acquires Sharklet Technologies
  • Table 46: Serum Institute of India Acquires Nanotherapeutics for USD78.2 Million
  • Table 47: Becton, Dickinson to Acquire C. R. Bard for USD24 Billion
  • Table 48: Shire May Acquire Radius Health
  • Table 49: PixarBio Terminates Acquisition of InVivo Therapeutics for USD77 Million
  • Table 50: Merck and Allergan May Acquire Biogen
  • Table 51: ICU Medical Acquires Hospira Infusion Systems Business from Pfizer
  • Table 52: PAVmed Raises USD5 Million in Private Placement of Notes and Warrants
  • Table 53: Becton, Dickinson to Raise USD725 Million in Public Offering of 2.133% Notes Due 2019
  • Table 54: Becton, Dickinson to Raise USD1 Billion in Public Offering of 2.404% Notes Due 2020
  • Table 55: Becton, Dickinson to Raise USD1.8 Billion in Public Offering of 2.894% Notes Due 2022
  • Table 56: Becton, Dickinson to Raise USD500 Million in Public Offering of Floating Rate Notes Due 2022
  • Table 57: Becton, Dickinson to Raise USD1.75 Billion in Public Offering of 3.363% Notes Due 2024
  • Table 58: Becton, Dickinson to Raise USD2.4 Billion in Public Offering of 3.7% Notes Due 2027
  • Table 59: Becton, Dickinson to Raise USD1.5 Billion in Public Offering of 4.669% Notes Due 2047
  • Table 60: Becton, Dickinson to Raise USD788 Million in Public Offering of 0.368% Notes Due 2019
  • Table 61: Skinvisible Raises USD0.2 Million in Issue of 10% Convertible Promissory Notes Due 2018
  • Table 62: Pfizer Raises USD1.3 Billion in Public Offering of Notes Due 2019
  • Table 63: Pfizer Raises USD1.06 Billion in Public Offering of Notes Due 2020
  • Table 64: Pfizer Raises USD1.06 Billion in Public Offering of 0.25% Notes Due 2022
  • Table 65: Pfizer Raises USD793.5 Million in Public Offering of 1% Notes Due 2027
  • Table 66: Pfizer Raises USD1.06 Billion in Private Placement of 4.2% Notes Due 2047
  • Table 67: Premier Biomedical Raises Funds in Third Tranche of Private Placement of 10% Notes Due 2016
  • Table 68: Catalent Prices Private Placement of 4.75% Notes Due 2024 for USD404.5 Million
  • Table 69: Becton Dickinson Prices Public Offering of 1% Notes Due 2022 for USD500 Million
  • Table 70: Becton Dickinson Prices Public Offering of 1.9% Notes Due 2026 for USD500 Million
  • Table 71: Pfizer Raises USD1 Billion in Public Offering of 1.7% Notes Due 2019
  • Table 72: Pfizer Raises USD1 Billion in Public Offering of 2.2% Notes Due 2021
  • Table 73: Pfizer Raises USD1.8 Billion in Public Offering of 3% Notes Due 2026
  • Table 74: Pfizer Raises USD1 Billion in Public Offering of 4% Notes Due 2036
  • Table 75: Pfizer Raises USD1.3 Billion in Public Offering of 4.125% Notes Due 2046
  • Table 76: Merck Raises USD544 Million in Public Offering of 1.375% Notes Due 2036
  • Table 77: Merck Raises USD544 Million in Public Offering of 0.5% Notes Due 2024
  • Table 78: KalVista Pharma Plans to Raise up to USD6 Million in Public Offering of Shares
  • Table 79: Clearside Biomedical Plans to Raise up to USD50 Million in Public Offering of Shares
  • Table 80: Delcath Systems to Raise USD2.4 Million in Private Placement of Series B Preferred Shares
  • Table 81: MannKind Plans to Raise Funds through Private Placement of Shares upon Exercise of Warrants
  • Table 82: PhaseRx Plans to Raise up to USD15 Million in Public Offering of Shares and Warrants
  • Table 83: EyeGate Pharma Raises USD10 Million in Public Offering of Shares and Warrants
  • Table 84: Zynerba Pharma Plans to Raise up to USD50 Million in Public Offering
  • Table 85: Savara Raises USD42.9 Million in Public Offering of Shares
  • Table 86: Premier Biomedical to Raise Funds through Public Offering of Shares
  • Table 87: MRI Interventions Raises USD13.3 Million in Private Placement of Units
  • Table 88: Alnylam Pharma Prices Public Offering of Shares for USD359.4 Million
  • Table 89: Corium International Raises USD40.3 Million in Public Offering of Shares
  • Table 90: Halozyme Therapeutics Raises USD143.8 Million in Public Offering of Shares
  • Table 91: Bellerophon Therapeutics to Raise USD30 Million in Private Placement of Shares
  • Table 92: Becton Dickinson Raises USD2.47 Billion in Public Offering of Shares
  • Table 93: Becton Dickinson Raises USD2.47 Billion in Public Offering of Depositary Shares
  • Table 94: Savara to Raise up to USD18 Million in Public Offering of Shares
  • Table 95: BioPharmX Raises USD5 Million in Private Placement of Shares and Warrants
  • Table 96: NanoCarrier Agrees to Invest in Tocagen
  • Table 97: Capnia Files Registration Statement for Secondary Offering of Shares
  • Table 98: Adamis Pharma Raises USD17.3 Million in Public Offering of Shares
  • Table 99: AngioDynamics Prices Public Offering of Shares for USD38 Million
  • Table 100: Tocagen Raises USD97.8 Million in IPO
  • Table 101: Premier Biomedical Raises USD0.3 Million in First Tranche of Private Placement of Shares and Warrants
  • Table 102: Catalyst Biosciences Raises USD20.7 Million in Public Offering of Units
  • Table 103: Alliqua BioMedical Raises USD2.8 Million in Private Placement of Shares
  • Table 104: Evoke Pharma Raises USD8 Million in Public Offering of Shares
  • Table 105: Windtree Therapeutics Raises USD10.5 Million in Private Placement of Units
  • Table 106: pSivida Plans to Raise Upto USD20 Million in Public Offering of Shares
  • Table 107: Galena Biopharma Raises Up to USD15.5 Million in Public Offering of Shares and Warrants
  • Table 108: Valeritas Files Registration Statement for IPO for up to USD50 Million
  • Table 109: PAVmed to Raise USD10.4 Million in Private Placement of Shares upon Exercise of Warrants
  • Table 110: Premier Biomedical Withdraws Public Offering of Shares
  • Table 111: PAVmed Raises Additional Funds in Second and Final Tranche of Private Placement of Units
  • Table 112: Corium International Raises USD20 Million in Public Offering of Shares
  • Table 113: Nu-Med Plus Raises USD0.3 Million in Private Placement of Shares
  • Table 114: Capnia Raises USD2 Million in First Tranche of Private Placement of Shares
  • Table 115: PAVmed Raises USD1.5 Million in First Tranche of Private Placement of Units
  • Table 116: Zynerba Pharma Announces Underwriters Exercise of Over-Allotment of Public Offering of Shares
  • Table 117: Heron Therapeutics Raises USD172.6 Million in Public Offering of Shares
  • Table 118: Braeburn Pharma to Raise USD40 Million in Private Placement of Shares
  • Table 119: Capnia Raises USD10 Million in Private Placement of Shares
  • Table 120: Milestone Scientific Completes Underwriters Partial Exercise of Over-Allotment Option of Public Offering of Shares
  • Table 121: AngioDynamics Prices Public Offering of Shares for USD32 Million
  • Table 122: PAVmed to Raise USD5.3 Million in Private Placement of Shares upon Exercise of Warrants
  • Table 123: ConvaTec Raises USD1.8 Billion in IPO
  • Table 124: Galena Biopharma to Raise Funds in Public Offering of Shares
  • Table 125: BioPharmX Raises USD12.5 Million in Public Offering of Units and Warrants
  • Table 126: Delcath Systems Prices Public Offering Shares and Warrants for USD1.3 Million
  • Table 127: T2 Biosystems Raises USD40 Million in Private Placement of Shares
  • Table 128: Intarcia Therapeutics Raises USD215 Million in First Tranche of Private Placement of Shares
  • Table 129: Catalent to Raise Funds through Public Offering of Shares
  • Table 130: MRI Interventions to Raise USD4.3 Million in Private Placement of Units
  • Table 131: BioMarin Pharma Prices Public Offering of Shares for USD720 Million
  • Table 132: Osprey Medical to Raise USD0.8 Million in Share Purchase Plan of CDIs
  • Table 133: Adamis Pharma to Raise USD11 Million in Private Placement of Units
  • Table 134: Dipexium Pharma Merges with PLx Pharma
  • Table 135: Infuseon Therapeutics Enters into Agreement with Oncosynergy
  • Table 136: Nobilis Therapeutics Enters into Agreement with Submersible Systems
  • Table 137: MannKind and One Drop to Enter into Agreement
  • Table 138: TWi Pharma Enters into Agreement with Intech Biopharm
  • Table 139: United Therapeutics Enters into Licensing Agreement with Respira Therapeutics
  • Table 140: Audax Medical Enters into Licensing Agreement with Northeastern University
  • Table 141: CannaRoyalty Enters into Licensing Agreement with NuTrae
  • Table 142: ViaCyte Enters into Research Agreement with W. L. Gore & Associates
  • Table 143: OncoSec Medical Enters into Agreement with Inhibrx
  • Table 144: Northwell Health Enters into Partnership with United Therapeutics
  • Table 145: PharmaJet Enters into Agreement with Serum Institute of India
  • Table 146: Aequus Pharma to Enter into Licensing Agreement with Transdermal Research Pharm Labs
  • Table 147: Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma
  • Table 148: Hikma Pharma Enters into Licensing Agreement with Orion
  • Table 149: A1 Group Enters into Licensing and Distribution Agreement ?with Novaceutical Sciences
  • Table 150: 3M Drug Delivery Systems Partners with Panacea Pharma
  • Table 151: Neuronex Enters Into Licensing Agreement With SK Biopharmaceuticals For DZNS Technology
  • Table 152: Pfizer Terminates its Licensing Agreement with pSivida
  • Table 153: Iatric Systems Enters into Agreement with Hospira
  • Table 154: Tepha Enters into Agreement with Metabolix
  • Table 155: Bayer Enters into Licensing Agreement with DelSiTech
  • Table 156: ALZYN Enters into Licensing Agreement with Transdermal Delivery Solutions
  • Table 157: Themis Medicare Enters into Agreement with Nevakar
  • Table 158: Qualcomm Partners with Boehringer Ingelheim Pharma
  • Table 159: SkinJect Enters into Licensing Agreement with University of Pittsburgh
  • Table 160: BioCorRx Enters into Licensing Agreement with Therakine
  • Table 161: 3i Group to Invest USD136 Million in Cirtec Medical Systems from Century Park Capital Partners
  • Table 162: AGIC Capital to Acquire Ritedose From Olympus Partners
  • Table 163: 410 Medical Raises USD3.3 Million in Series A Financing
  • Table 164: Mentor Capital Invests USD1 Million in GW Pharma
  • Table 165: Otomagnetics Raises USD0.3 Million in Venture Financing
  • Table 166: Pharmajet Raises USD3 Million in Venture Financing
  • Table 167: 410 Medical Raises Additional USD2.1 Million in Series A Financing
  • Table 168: NexGen Medical Systems Raises USD1.5 Million in Venture Financing
  • Table 169: Xeris Pharma Raises Additional USD30 Million in Series C Financing
  • Table 170: Respira Therapeutics to Raise Funds through Series B Preferred Stock Financing
  • Table 171: Ivenix Raises USD50 Million in First Tranche of Equity Financing
  • Table 172: Ivenix Raises USD10 Million in Venture Financing
  • Table 173: Surefire Medical Raises USD12.8 Million in First Round of Series D Financing
  • Table 174: Unilife Raises USD5 Million in Venture Financing
  • Table 175: iVeena Delivery Systems to Raise USD1 Million in Venture Financing
  • Table 176: NapaJen Pharma to Raise Funds in Equity Financing
  • Table 177: Impel NeuroPharma Raises USD21 Million in First Tranche of Series C Financing
  • Table 178: Tocagen Raises USD2.73 Million in Venture Financing
  • Table 179: Impel NeuroPharma Raises USD22.3 Million in Venture Financing
  • Table 180: Unilife Raises USD10.6 Million in Financing Round
  • Table 181: Propeller Health Raises USD21.5 Million in Series C Financing
  • Table 182: BioQ Pharma Raises USD15 Million in Financing Round
  • Table 183: Enable Injections Raises USD30 Million in Series A Financing
  • Table 184: QuiO Technologies Raises USD1.05 Million in Seed Financing
  • Table 185: Impel NeuroPharma Raises USD0.08 Million in Venture Financing
  • Table 186: Kaio Therapy Raises USD0.2 Million in Venture Financing
  • Table 187: Credence MedSystems Raises USD15 Million in Series A Financing
  • Table 188: Chrono Therapeutics Raises USD47.6 Million in Series B Financing
  • Table 189: Enable Injections Raises USD10 Million in Venture Financing
  • Table 190: Fe3 Medical Raises Additional USD3.5 Million in Series B Financing Round

List of Figures

  • Figure 1: Drug Delivery Devices Market, United States, Revenue ($m), USD Constant, 2009-2023
  • Figure 2: Drug Delivery Devices Market, United States, Revenue Mix ($m), 2016
  • Figure 3: Drug Delivery Devices Market, United States, Category Contribution (%), 2016
  • Figure 4: Drug Delivery Devices Market, United States, Category Comparison by Revenue ($m), 2009-2023
  • Figure 5: Drug Delivery Devices Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016
  • Figure 6: Drug Delivery Devices Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023
  • Figure 7: Drug Delivery Devices Market, United States, Volume (Units), 2009-2023
  • Figure 8: Drug Delivery Devices Market, United States, Volume (Units), Historic, 2009-2016
  • Figure 9: Drug Delivery Devices Market, United States, Volume (Units), Forecast, 2016-2023
  • Figure 10: Drug Delivery Devices Market, United States, Company Share (%) 2016
  • Figure 11: Central Venous Catheters Market, United States, Revenue Mix ($m), 2016
  • Figure 12: Central Venous Catheters Market, United States, Segment Contribution (%), 2016
  • Figure 13: Central Venous Catheters Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016
  • Figure 14: Central Venous Catheters Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023
  • Figure 15: Central Venous Catheters Market, United States, Volume (Units), Historic, 2009-2016
  • Figure 16: Central Venous Catheters Market, United States, Volume (Units), Forecast, 2016-2023
  • Figure 17: Central Venous Catheters Market, United States, Company Share (%) 2016
  • Figure 18: Infusion Systems Market, United States, Revenue Mix ($m), 2016
  • Figure 19: Infusion Systems Market, United States, Segment Contribution (%), 2016
  • Figure 20: Infusion Systems Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016
  • Figure 21: Infusion Systems Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023
  • Figure 22: Ambulatory Infusion Pumps Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016
  • Figure 23: Syringe Pumps Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016
  • Figure 24: Ambulatory Infusion Pumps Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023
  • Figure 25: Syringe Pumps Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023
  • Figure 26: Infusion Systems Market, United States, Volume (Units), Historic, 2009-2016
  • Figure 27: Infusion Systems Market, United States, Volume (Units), Forecast, 2016-2023
  • Figure 28: Ambulatory Infusion Pumps Market, United States, Volume (Units), Historic, 2009-2016
  • Figure 29: Syringe Pumps Market, United States, Volume (Units), Historic, 2009-2016
  • Figure 30: Ambulatory Infusion Pumps Market, United States, Volume (Units), Forecast, 2016-2023
  • Figure 31: Syringe Pumps Market, United States, Volume (Units), Forecast, 2016-2023
  • Figure 32: Infusion Systems Market, United States, Company Share (%) 2016
  • Figure 33: Needle Free Injections Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016
  • Figure 34: Needle Free Injections Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023
  • Figure 35: Needle Free Injections Market, United States, Volume (Units), Historic, 2009-2016
  • Figure 36: Needle Free Injections Market, United States, Volume (Units), Forecast, 2016-2023
  • Figure 37: Needle Free Injections Market, United States, Company Share (%) 2016
  • Figure 38: Metered Dose Inhaler Devices Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016
  • Figure 39: Metered Dose Inhaler Devices Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023
  • Figure 40: Metered Dose Inhaler Devices Market, United States, Volume (Units), Historic, 2009-2016
  • Figure 41: Metered Dose Inhaler Devices Market, United States, Volume (Units), Forecast, 2016-2023
  • Figure 42: Metered Dose Inhaler Devices Market, United States, Company Share (%) 2016
Back to Top